About This Trial
Anti-amyloid antibody targeting N3pG amyloid for earlier-stage Alzheimer's patients.
Primary Endpoints
- iADRS score change
- Amyloid plaque clearance
Latest Update
February 2026
FDA approved Kisunla (donanemab) in July 2025. Post-marketing study confirms 35% slowing of decline at 18 months.
Lead Investigators
DR
Dr. Reisa Sperling Director, Center for Alzheimer Research, BWH